Pre-made Lifastuzumab Vedotin benchmark antibody (Whole mAb ADC, anti-SLC34A2 therapeutic antibody, Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-893

Pre-made Lifastuzumab Vedotin benchmark antibody (Whole mAb ADC, anti-SLC34A2 therapeutic antibody, Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lifastuzumab vedotin (INN;[1] development code DNIB6A) is a monoclonal antibody designed for the treatment of cancer.[2]

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-893-1mg 1mg 4635
GMP-Bios-INN-893-10mg 10mg Inquiry
GMP-Bios-INN-893-100mg 100mg Inquiry
GMP-Bios-INN-893-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Lifastuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Slc34A2 Antibody: Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM therapeutic antibody Drug Conjugate
INN Name Lifastuzumab Vedotin
TargetSLC34A2
FormatWhole mAb ADC
DerivationHumanized
Species Reactivityhuman
CH1 IsotypeIgG1 - kappa
VD LCIgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesRoche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0